David Luther joins MISSION Therapeutics
pharmafile | October 6, 2015 | Appointment | Manufacturing and Production, Medical Communications, Sales and Marketing |
Cambridge, UK-based MISSION Therapeutics has announced the appointment of David Luther as chief financial officer.
Luther brings more than 25 years’ financial and operational experience, across the healthcare, FMCG and pharmaceutical industries. He comments: “I am very enthusiastic about joining the highly experienced MISSION management team and look forward to working with them and the Company’s investors to create and deliver value from the diverse therapeutic opportunities generated by the Company’s discovery platform.”
The new CFO joins MISSION from Spotless Group, a private equity-backed FMCG business, having successfully supported them in a trade exit to Henkel. He served as VP Finance for commercial and supply chain operations in the UK, Ireland and Italy.
Prior to the Spotless Group, Mr Luther was finance director for the Italian operations of Aptuit, a global healthcare contract services organisation, and prior to this spent 15 years at GlaxoSmithKline (GSK). At GSK, Mr Luther held a number of senior roles, including director, Corporate Development, responsible for M&A transactions, finance director Neurosciences, helping to create GSK’s innovative drug discovery concept, commercial finance director positions in Hungary and Poland, and initially as an operations consultant, performing consulting and compliance reviews across the organisation.
Mr Luther trained and qualified as an ACA with KPMG and has a BSc in Biochemistry from the University of Surrey. He has lived and worked in the UK, USA, Poland, Hungary, Italy and South Africa.
Dr Anker Lundemose, CEO of MISSION Therapeutics, says: “David’s financial acumen, extensive experience and exemplary track record in both large pharma and private equity-backed companies will be invaluable to MISSION. This welcome appointment comes at a pivotal moment in our corporate development and complements the senior management team as our assets grow with the success of our discovery programmes.”
